Share price · GNTA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GNTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+20.6%
- 2 Nov 2026+32.1%
- 1 Oct 2026+14.8%
Nothing announced by GNTA that day or the session before.
- 2 Jun 2026+33.3%
Nothing announced by GNTA that day or the session before.
- 1 Jun 2026+60.2%
- Day beforeGenenta Science S.p.A.: 6-K filing
- 29 May 2026+15.1%
- 27 May 2026+37.3%
Nothing announced by GNTA that day or the session before.
- 9 Feb 2026+14.3%
Nothing announced by GNTA that day or the session before.
- 5 Feb 2026-15.4%
Nothing announced by GNTA that day or the session before.
- 30 Jan 2026-15.7%
Nothing announced by GNTA that day or the session before.
Share of unusual movement by asset
For each asset, the share of GNTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 32% |
| Sessions with no dated event | — | 68% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Interferon-alpha2 (myeloid-specific expression) · Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsGene therapy / editing | Glioblastoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $3.1M | $6.5M+ $27M short-term inv. | $1.9M-$7.8M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $5.2M | $4.8M+ $8.4M short-term inv. | $2.4M-$6.8M operating cash flow | report ↗ |
| 2023-FY | — | $7.0M | $4.1M+ $17M short-term inv. | $3.1M-$12M operating cash flow | report ↗ |
| 2022-FY | — | $5.6M | $32M | $2.2M-$7.8M operating cash flow | report ↗ |
| 2021-FY | — | $4.0M | $42M | $1.6M-$8.2M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-03-30 | Paracchi Pierluigi · director, Chief Executive Officer, 10% owner | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-03-30 | SLANSKY RICHARD B · Chief Financial Officer | Award / grant (derivative) | 80,000 | — | — | Form 4 |
| 2026-03-30 | Mutti Miguel Maria · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-30 | Sharei Armon · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-30 | PARACCHI GIACOMOANTONIO · director | Award / grant (derivative) | 20,000 | — | — | Form 4 |
| 2026-03-30 | Galimi Francesco · director, CMO& Head of Development | Award / grant (derivative) | 20,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 11 reporting institutions held 1.0M shares ($696K, 4.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Eurizon Capital SGR S.p.A. | 360,000 | $242K |
| 2 | Allianz SE | 234,050 | $157K |
| 3 | AlTi Global, Inc. | 200,288 | $135K |
| 4 | SmartHarvest Portfolios, LLC | 134,447 | $90K |
| 5 | Independent Advisor Alliance | 37,036 | $25K |
| 6 | XTX Topco Ltd | 24,527 | $16K |
| 7 | MORGAN STANLEY | 15,420 | $10K |
| 8 | GAMMA Investing LLC | 14,288 | $10K |
| 9 | Simplicity Wealth,LLC | 12,211 | $8K |
| 10 | UBS Group AG | 3,107 | $2K |
| 11 | Farther Finance Advisors, LLC | 3 | $2 |